Researchers have confirmed major co-morbidities that elevate the risk of dying from the coronavirus.

These include cardiovascular disease, hypertension, diabetes, congestive heart failure, chronic kidney disease, stroke, and cancer.

The findings were published in the journal PLOS ONE. The researchers of the study believe that this will help health officials improve patient care and develop interventions that can target these high-risk populations.

Study author Paddy Ssentongo from the Penn State University in the US said in a statement: “This study suggests that these chronic conditions are not just common in patients with Covid-19, but their presence is a warning sign to a higher risk of death.”

Methodology

For the study, the researchers carried out a systematic review and meta-analysis to determine which chronic conditions put hospitalised patients at risk of dying from Covid-19.

They explored 11 co-existing conditions that pose a risk of severe disease and death among Covid-19 patients,

Read More



a man standing in front of a building: Matthew Horwood/Getty Images


© Provided by Business Insider
Matthew Horwood/Getty Images

  • The UK government introduced a 10 p.m. curfew for pubs, bars, and restaurants, and compulsory table service as part of its latest coronavirus safety measures.
  • Industry bodies have described this as “another crushing blow” that will “devastate” the sector well into 2021.
  • Two in five adults said they will go out less often as a result of curfew, according to a survey from market research company CGA.
  • The curfew will also affect takeaways. CEOs of fast-food giants KFC and Pizza Hut warned that the curfew could have a “catastrophic impact.”
  • Visit Business Insider’s homepage for more stories.

England’s new 10 p.m. curfew at pubs, bars, and restaurants — designed to push down COVID-19 cases — is “another crushing blow” to struggling businesses now facing closure, owners have said.

Loading...

Load Error

Nearly a quarter (23%) of members of the UK’s biggest pub and

Read More

Sept. 25 (UPI) — Being wealthy appears to reduce a person’s risk for heart disease — at least in the United States — based on the findings of an analysis published Friday by JAMA Network Open.

The prevalence of conditions such as congestive heart failure, angina and stroke among individuals with incomes in the top 20% nationally ranged from roughly 1% to 1.5%, the data showed.

For the remaining 80% of people, however, the prevalence of these conditions ranged from about 2.8% to 3.1%, the researchers said.

Meanwhile, the prevalence of heart attack was about 3.9% among the poorest 80%, compared to about 2.1% for the wealthiest 20%, researchers found.

“Our results suggest that the public conversation around income inequality should move beyond a ‘top 1%’ narrative to one that acknowledges that the richest 20% of Americans are ‘pulling away’ on health from the poorest 80%,” study co-author Dr. Salma

Read More

Dyne Therapeutics, a preclinical biotech developing oligonucleotide therapies for rare muscular diseases, announced terms for its IPO on Thursday.

The Waltham, MA-based company plans to raise $175 million by offering 10.3 million shares at a price range of $16 to $18. At the midpoint of the proposed range, Dyne Therapeutics would command a fully diluted market value of $782 million.

The company is using its proprietary FORCE platform to develop a pipeline of programs to address genetically-driven muscle diseases with high unmet need. This includes candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and facioscapulohumeral dystrophy (FSHD). Dyne expects to submit INDs for candidates in its DM1, DMD, and FSHD programs between the 4Q21 and 4Q22.

Dyne Therapeutics was founded in 2017 and plans to list on the Nasdaq under the symbol DYN. J.P. Morgan, Jefferies, Piper Sandler and Stifel are the joint bookrunners on the

Read More